vs
DYNAVAX TECHNOLOGIES CORP（DVAX）与RE/MAX Holdings, Inc.（RMAX）财务数据对比。点击上方公司名可切换其他公司
DYNAVAX TECHNOLOGIES CORP的季度营收约是RE/MAX Holdings, Inc.的1.3倍（$94.9M vs $71.1M），DYNAVAX TECHNOLOGIES CORP净利率更高（28.4% vs 2.0%，领先26.4%），DYNAVAX TECHNOLOGIES CORP同比增速更快（17.7% vs -1.8%），RE/MAX Holdings, Inc.自由现金流更多（$33.5M vs $32.6M），过去两年DYNAVAX TECHNOLOGIES CORP的营收复合增速更高（30.6% vs -4.7%）
Dynavax Technologies Corp是一家处于商业化阶段的生物制药企业，专注于研发和生产针对传染病的创新疫苗及免疫疗法，核心上市产品为成人乙肝疫苗Heplisav-B，主要市场覆盖北美与欧洲，同时拥有多款针对未满足公共卫生需求的在研产品。
RE/MAX是全球知名的房地产特许经营机构，业务遍布全球一百多个国家和地区，旗下拥有数千家门店，总计超过十万名房产经纪人，在国际房产中介领域拥有极高的品牌知名度与市场影响力。
DVAX vs RMAX — 直观对比
营收规模更大
DVAX
是对方的1.3倍
$71.1M
营收增速更快
DVAX
高出19.5%
-1.8%
净利率更高
DVAX
高出26.4%
2.0%
自由现金流更多
RMAX
多$912.0K
$32.6M
两年增速更快
DVAX
近两年复合增速
-4.7%
损益表 — Q3 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $94.9M | $71.1M |
| 净利润 | $26.9M | $1.4M |
| 毛利率 | — | — |
| 营业利润率 | 22.4% | 13.1% |
| 净利率 | 28.4% | 2.0% |
| 营收同比 | 17.7% | -1.8% |
| 净利润同比 | 53.0% | -75.2% |
| 每股收益（稀释后） | $0.21 | — |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收DVAXRMAX
| Q4 25 | — | $71.1M | ||
| Q3 25 | $94.9M | $73.2M | ||
| Q2 25 | $95.4M | $72.8M | ||
| Q1 25 | $68.2M | $74.5M | ||
| Q4 24 | $72.0M | $72.5M | ||
| Q3 24 | $80.6M | $78.5M | ||
| Q2 24 | $73.8M | $78.5M | ||
| Q1 24 | $50.8M | $78.3M |
净利润DVAXRMAX
| Q4 25 | — | $1.4M | ||
| Q3 25 | $26.9M | $4.0M | ||
| Q2 25 | $18.7M | $4.7M | ||
| Q1 25 | $-96.1M | $-2.0M | ||
| Q4 24 | $7.0M | $5.8M | ||
| Q3 24 | $17.6M | $966.0K | ||
| Q2 24 | $11.4M | $3.7M | ||
| Q1 24 | $-8.7M | $-3.4M |
营业利润率DVAXRMAX
| Q4 25 | — | 13.1% | ||
| Q3 25 | 22.4% | 25.0% | ||
| Q2 25 | 15.1% | 19.3% | ||
| Q1 25 | -34.7% | 7.2% | ||
| Q4 24 | -2.3% | 5.9% | ||
| Q3 24 | 12.5% | 19.4% | ||
| Q2 24 | 7.0% | 20.6% | ||
| Q1 24 | -35.0% | 5.8% |
净利率DVAXRMAX
| Q4 25 | — | 2.0% | ||
| Q3 25 | 28.4% | 5.4% | ||
| Q2 25 | 19.6% | 6.4% | ||
| Q1 25 | -141.0% | -2.6% | ||
| Q4 24 | 9.8% | 8.0% | ||
| Q3 24 | 21.8% | 1.2% | ||
| Q2 24 | 15.4% | 4.7% | ||
| Q1 24 | -17.2% | -4.3% |
每股收益（稀释后）DVAXRMAX
| Q4 25 | — | — | ||
| Q3 25 | $0.21 | — | ||
| Q2 25 | $0.14 | — | ||
| Q1 25 | $-0.77 | — | ||
| Q4 24 | $0.07 | — | ||
| Q3 24 | $0.12 | — | ||
| Q2 24 | $0.08 | — | ||
| Q1 24 | $-0.07 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $160.2M | $118.7M |
| 总债务越低越好 | — | $432.2M |
| 股东权益账面价值 | $534.1M | $452.4M |
| 总资产 | $946.5M | $582.5M |
| 负债/权益比越低杠杆越低 | — | 0.96× |
8季度趋势，按日历期对齐
现金及短期投资DVAXRMAX
| Q4 25 | — | $118.7M | ||
| Q3 25 | $160.2M | $107.5M | ||
| Q2 25 | $99.1M | $94.3M | ||
| Q1 25 | $51.7M | $89.1M | ||
| Q4 24 | $95.9M | $96.6M | ||
| Q3 24 | $119.3M | $83.8M | ||
| Q2 24 | $112.5M | $66.1M | ||
| Q1 24 | $132.0M | $82.1M |
总债务DVAXRMAX
| Q4 25 | — | $432.2M | ||
| Q3 25 | — | $433.3M | ||
| Q2 25 | — | $434.4M | ||
| Q1 25 | — | $435.3M | ||
| Q4 24 | — | $436.2M | ||
| Q3 24 | — | $437.2M | ||
| Q2 24 | — | $438.1M | ||
| Q1 24 | — | $439.0M |
股东权益DVAXRMAX
| Q4 25 | — | $452.4M | ||
| Q3 25 | $534.1M | $448.1M | ||
| Q2 25 | $494.2M | $442.4M | ||
| Q1 25 | $530.9M | $433.5M | ||
| Q4 24 | $596.8M | $429.5M | ||
| Q3 24 | $681.4M | $423.1M | ||
| Q2 24 | $642.8M | $418.4M | ||
| Q1 24 | $618.5M | $412.0M |
总资产DVAXRMAX
| Q4 25 | — | $582.5M | ||
| Q3 25 | $946.5M | $582.2M | ||
| Q2 25 | $918.4M | $574.8M | ||
| Q1 25 | $945.9M | $571.4M | ||
| Q4 24 | $986.3M | $581.6M | ||
| Q3 24 | $1.1B | $578.6M | ||
| Q2 24 | $1.0B | $571.4M | ||
| Q1 24 | $986.6M | $566.7M |
负债/权益比DVAXRMAX
| Q4 25 | — | 0.96× | ||
| Q3 25 | — | 0.97× | ||
| Q2 25 | — | 0.98× | ||
| Q1 25 | — | 1.00× | ||
| Q4 24 | — | 1.02× | ||
| Q3 24 | — | 1.03× | ||
| Q2 24 | — | 1.05× | ||
| Q1 24 | — | 1.07× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $33.8M | $40.9M |
| 自由现金流经营现金流 - 资本支出 | $32.6M | $33.5M |
| 自由现金流率自由现金流/营收 | 34.4% | 47.1% |
| 资本支出强度资本支出/营收 | 1.3% | 10.4% |
| 现金转化率经营现金流/净利润 | 1.26× | 28.39× |
| 过去12个月自由现金流最近4个季度 | $80.5M | $56.8M |
8季度趋势，按日历期对齐
经营现金流DVAXRMAX
| Q4 25 | — | $40.9M | ||
| Q3 25 | $33.8M | $17.7M | ||
| Q2 25 | $23.4M | $4.6M | ||
| Q1 25 | $-19.6M | $5.7M | ||
| Q4 24 | $53.0M | $59.7M | ||
| Q3 24 | $19.5M | $17.6M | ||
| Q2 24 | $10.7M | $15.9M | ||
| Q1 24 | $-16.7M | $9.4M |
自由现金流DVAXRMAX
| Q4 25 | — | $33.5M | ||
| Q3 25 | $32.6M | $16.4M | ||
| Q2 25 | $22.0M | $2.9M | ||
| Q1 25 | $-23.6M | $4.0M | ||
| Q4 24 | $49.5M | $53.0M | ||
| Q3 24 | $18.1M | $16.3M | ||
| Q2 24 | $9.9M | $14.0M | ||
| Q1 24 | $-17.4M | $6.8M |
自由现金流率DVAXRMAX
| Q4 25 | — | 47.1% | ||
| Q3 25 | 34.4% | 22.4% | ||
| Q2 25 | 23.0% | 4.0% | ||
| Q1 25 | -34.6% | 5.3% | ||
| Q4 24 | 68.8% | 73.2% | ||
| Q3 24 | 22.5% | 20.8% | ||
| Q2 24 | 13.5% | 17.8% | ||
| Q1 24 | -34.3% | 8.6% |
资本支出强度DVAXRMAX
| Q4 25 | — | 10.4% | ||
| Q3 25 | 1.3% | 1.8% | ||
| Q2 25 | 1.5% | 2.2% | ||
| Q1 25 | 5.8% | 2.3% | ||
| Q4 24 | 4.8% | 9.1% | ||
| Q3 24 | 1.7% | 1.7% | ||
| Q2 24 | 1.1% | 2.4% | ||
| Q1 24 | 1.5% | 3.3% |
现金转化率DVAXRMAX
| Q4 25 | — | 28.39× | ||
| Q3 25 | 1.26× | 4.45× | ||
| Q2 25 | 1.25× | 0.97× | ||
| Q1 25 | — | — | ||
| Q4 24 | 7.52× | 10.28× | ||
| Q3 24 | 1.11× | 18.22× | ||
| Q2 24 | 0.94× | 4.29× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
DVAX
| HEPLISAVB | $90.0M | 95% |
| US Department Of Defense | $4.7M | 5% |
RMAX
| Franchising Segment | $50.1M | 70% |
| Broker Fees | $13.9M | 20% |
| Annual Dues | $7.4M | 10% |
